MTP-CA Applauds The Release Of Canada’s First ALS Management Guidelines

November 18, 2020

Mitsubishi Tanabe Pharma Canada (MTP-CA) congratulates the authors of the Canadian best practices recommendations for the care and management of patients living with amyotrophic lateral sclerosis (ALS) for publishing this important work in the Canadian Medical Association
Journal (CMAJ). We recognize the hard work and commitment required to develop guidelines and applaud the authors, development committee and ALS Canada for their dedication to the ALS community in Canada.

The guidelines establish a national standard of care for the rare neurodegenerative disease, providing guidance for ALS clinicians, allied health professionals and primary care providers. We support the Canadian best practice recommendations for the management of ALS, which we hope will be very beneficial to the patient community in Canada.

MTP-CA is deeply committed to making a real difference in the lives of Canadians living with ALS. We are dedicated to ongoing research to support this patient community and to bringing new therapeutic options to disease areas with unmet needs.